

Notable research on anthracyclines in breast cancer

De Laurentiis M, Canello G, D'Agostino D, et al: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. *JCO* 26:44-53, 2008.

Dhesy-Thind B, Pritchard KI, Messersmith H, et al: HER2/neu in systemic therapy for women with breast cancer: a systemic review. *Breast Cancer Res Treat* 109:209-229, 2008.

Gennari A, Sormani MP, Pronzato P, et al: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. *J Natl Cancer Inst* 100:14-20, 2008.

Goldstein LJ, O'Neill A, Sparano JA, et al: Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup trial E2197. *JCO* 26:4092-4099, 2008.

Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al: Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. *JCO* 26:1980-1986, 2008.

Pritchard KI, Messersmith H, Elavathil L, et al: HER2 and Topoisomerase II as predictors of response to chemotherapy. *JCO* 25:736-744, 2008.

Smith I, Proctor M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. *Lancet* 369:29-36, 2007.

Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. *N Engl J Med* 354:809-20, 2006.

Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. *JCO* 24: 5381-5387, 2006.

Early Breast Cancer Trialists' Collaborative Group: Effects of Chemotherapy and hormonal therapy for early +breast cancer on recurrence and 15 year survival: an overview of the randomized trials. *Lancet* 365:1687-1717, 2005.

Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* 353:1673-84: 2005.

Slamon D, Eirmann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin

and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. *Breast Cancer Res Treat* 94:S5, supplement 1, 2005.

Bartlett JMS, Munro A, Cameron DA, et al: Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. *JCO* online, September 2, 2008; doi:10.1200/JCO.2007.14.6597.

Theodoulou M, Seidman AD: Cardiac effects of adjuvant therapy for breast cancer. *Semin Oncol* 30:730-739, 2003.